Skip to main content

Table 4 Summary of treatment outcome

From: An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

Parameter

Treatment Set

N = 88

PFS

 Patients who progressed or died, n (%)

70 (80)

 Median, months [95% CI]

17.0 [12.9–23.3]

Tumor response, n (%)

 Best overall response

  Complete response

2 (2)

  Partial response

69 (78)

  Stable disease

12 (14)

  Progressive disease

2 (2)

  Not evaluable

3 (3)

 ORR, n (%) [95% CI]

71 (80.7) [70.9–88.3]

Disease control

 DCR, n (%) [95% CI]

83 (94.3) [87.2–98.1]

 Duration of disease control, months [95% CI]

18.3 [13.6–23.7]

  1. CI confidence interval, DCR disease control rate, ORR objective response rate, PFS progression-free survival